** U.S.-listed shares of Israel-based drugmaker Teva Pharmaceutical Industries TEVA.TA, TEVA.N rises 6.6% to $17.32 premarket
** TEVA and partner Biotech Alvotech ALVO.O say the U.S. FDA has accepted for review its marketing application for a biosimilar or close copy of Regeneron's REGN.O Eylea
** Co says AVT06 is a proposed biosimilar of Eylea's 2 milligram dose which is used to treat eye disorders like macular degeneration, macular edema and retinopathy
** Co, ALVO expects regulatory decision for AVT06 by Q4 2025
** Some key patents of Eylea are set to expire in 2027, according to a regulatory filing
** ALVO is also developing AVT29, a biosimilar for Eylea HD, a 8 mg dose of the drug
** Amgen AMGN.O will also make its biosimilar version of Eylea available to patients after a U.S. appeals court rejected REGN's request to block its launch
** In the last 12 months, TEVA has risen 32.4%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。